Stoke Therapeutics, Inc. financial data

Symbol
STOK on Nasdaq
Industry
Pharmaceutical Preparations
Location
45 Wiggins Avenue, Bedford, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
ASOthera Pharmaceuticals, Inc. (to 11/24/2014)
Latest financial report
10-Q - Q3 2024 - Nov 5, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 597 % -33.8%
Debt-to-equity 33.5 % -6.31%
Return On Equity -54.5 % -0.3%
Return On Assets -40.8 % -2%
Operating Margin -701 % +42.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 53M shares +18.6%
Common Stock, Shares, Outstanding 52.9M shares +19.5%
Entity Public Float 290M USD -2.36%
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 56.3M shares +27.3%
Weighted Average Number of Shares Outstanding, Diluted 56.3M shares +27.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 16.7M USD +81%
Research and Development Expense 87.5M USD +7.33%
General and Administrative Expense 46.6M USD +16.1%
Operating Income (Loss) -117M USD -4.4%
Nonoperating Income (Expense) 11.8M USD +32.1%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -105M USD -1.99%
Earnings Per Share, Basic -2.11 USD/shares +12.8%
Earnings Per Share, Diluted -2.11 USD/shares +12.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 150M USD -21%
Other Assets, Current 3.81M USD -10.8%
Assets, Current 254M USD +10.3%
Property, Plant and Equipment, Net 4.33M USD -30.3%
Operating Lease, Right-of-Use Asset 4.93M USD +59.8%
Assets 293M USD +22.3%
Accounts Payable, Current 2.49M USD -19.2%
Liabilities, Current 49.9M USD +97.9%
Operating Lease, Liability, Noncurrent 3.01M USD +267%
Other Liabilities, Noncurrent 3.05M USD +218%
Liabilities 61.2M USD -8.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 166K USD
Retained Earnings (Accumulated Deficit) -480M USD -28.1%
Stockholders' Equity Attributable to Parent 232M USD +34.2%
Liabilities and Equity 293M USD +22.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -24.6M USD -15%
Net Cash Provided by (Used in) Financing Activities 1.72M USD -96.2%
Net Cash Provided by (Used in) Investing Activities 9.99M USD -81.2%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 52.9M shares +19.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -12.9M USD -117%
Deferred Tax Assets, Valuation Allowance 133M USD +36.1%
Deferred Tax Assets, Gross 133M USD +36.1%
Operating Lease, Liability 5.31M USD +60%
Depreciation 563K USD -5.7%
Payments to Acquire Property, Plant, and Equipment 12K USD -92.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -105M USD -3.24%
Lessee, Operating Lease, Liability, to be Paid 5.88M USD +72.2%
Property, Plant and Equipment, Gross 12.5M USD +14.8%
Operating Lease, Liability, Current 2.3M USD -8.01%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.66M USD +2.03%
Lessee, Operating Lease, Liability, to be Paid, Year One 653K USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +106%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 572K USD +490%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.56M USD +1391%
Deferred Tax Assets, Operating Loss Carryforwards 52.6M USD -8.84%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 712M USD +30%
Share-based Payment Arrangement, Expense 26.4M USD +5.6%